RUSNANO No Longer Part of PET-Technology, National Network of Nuclear Medicine
JSC RUSNANO sold its 49.9% shares in the portfolio company PET-Technology LLC to the Pharmstandard Group. The Pharmstandard Group’s stake in PET-Technology has increased from 50.1% to 100%. RUSNANO’s Board of Directors and FAS Russia (Federal Antimonopoly Service) approved the transaction whose cost amounted to RUB 2.9 bln, which exceeds RUSNANO’s investment in PET-Technology by RUB 700 mln. The share in the company was fully paid for. RUSNANO’s IRR was 6.3% on selling its stake and corresponded to the market earnings in the health care sector. RUSNANO was an investor in PET-Technology from its inception in 2011.
The national network of nuclear medicine, PET-Technology, founded 11 operational diagnostic PET/CT centres in the regions of central Russia, in Moscow, Kursk, Belgorod, Yekaterinburg, Ufa, Lipetsk, Oryol, Tambov, Tolyatti, Samara, and Rostov-on-Don. The Project includes two radiopharmaceutical (RP) factories in Ufa and Yelets equipped with cyclotron complexes, laboratories for radiopharmaceuticals synthesis as well as the CyberKnife therapy device for radiosurgery. The portfolio company invested RUB 4.6 bln in developing the network.
The world-renowned PET/CT method is a combination of positron emission and computer tomography that makes cancer diagnosis at an early stage and selection of an appropriate treatment possible. The PET-Technology network has a 50% share of the Russian PET/CT diagnostic market and is a leader in providing diagnostic services among private players. Since the opening of the first PET-Technology Centre in 2014, 72,000 patients have been diagnosed using the PET/CT method and more than 1,300 individuals have undergone radiotherapy using CyberKnife.
According to the Managing Director for the Investment Activity Olga Shpichko at RUSNANO Management Company: “In 7 years, RUSNANO has completed its mission of creating the largest private company in the Russian market for diagnosing oncological diseases using modern means that integrates radiopharmaceutical production, its logistics system and diagnostics. The creation of the national network of PET/CT centres in Russian regions became a stepping-stone towards establishing the nuclear medicine diagnostic market providing cutting-edge services in the country. The Project has had stable financial results, by the end of 2017 PET-Technology’s revenue exceeded RUB 1 bln, and based on our forecasts, it will increase 1.5 times in 2018. This will enable this specialist investor to continue its geographic network expansion and increase its range of services in the nuclear medicine sector.”
RUSNANO Joint-Stock Company was founded in March 2011 through reorganization of state corporation Russian Corporation of Nanotechnologies. JSC RUSNANO contributes to implementation of the state policy on the development of the nanotechnology industry by investing directly and through investment funds of nanotechnology in financially effective high-technology projects providing the development of new production facilities in the Russian Federation. Its primary investment focus is in electronics, optoelectronics and telecommunications, healthcare and biotechnology, metallurgy and metalwork, energy, mechanical engineering and instrument making, construction and industrial materials, chemicals and petrochemicals. 100 percent of RUSNANO’s shares are state owned. Thanks to RUSNANO’s investments, there are currently 115 factories and R&D Centers opened in 37 regions in Russia. JSC RUSNANO has profit for the last 5 years.
Management of assets of RUSNANO JSC is carried out by Limited Liability Company established in December 2013, RUSNANO Management Company. Anatoly Chubais is the Chairman of its Executive Board.
Work to establish nanotechnology infrastructure and carry out educational programs is fulfilled by RUSNANO’s Fund for Infrastructure and Educational Programs, which was also established during the reorganization of the Russian Corporation of Nanotechnologies.